DIAMYD MEDICAL

Targeting the Underlying Causes of Diabetes


 

Vision

There is a cure for autoimmune diabetes

What We Do

We develop therapies using our in-licensed substances GAD and GABA for the prevention or treatment of diabetes and other serious inflammatory diseases

Diamyd Medical is a Swedish clinical-stage diabetes company active in the field of pharmaceutical development.

Two disease-modifying therapies are being developed, the antigen-specific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapy Remygen®.

Diamyd® and Remygen® target the underlying causes of diabetes, the dysfunction and loss of the pancreatic beta cells. Diamyd® and Remygen® are currently being evaluated in clinical trials.

Diamyd Medical’s shares are traded on Nasdaq First North, ticker DMYD B.

 

TARGETING THE UNDERLYING CAUSES OF DIABETES

Diamyd® and Remygen™ are drugs in clinical development phase targeting the underlying causes of diabetes, the dysfunction and loss of the pancreatic beta cells.

 
 

Both Diamyd® and Remygen® are at an exciting stage with an opportunity to reach the market faster than would otherwise be expected for drugs at the same development phase.

Ulf Hannelius
President and CEO, Diamyd Medical AB
 

 

BUSINESS MODEL

Diamyd Medical is a cost-efficient and flexible company with substantial experience of pharmaceutical and technical development. Parts of the operations are outsourced to qualified partners with expert knowledge while the company employees manage and implement clinical and preclinical development, regulatory affairs, production and business development.